The legal landscape surrounding Oxbryta has shifted rapidly since the drug’s withdrawal from the market. New filings, court rulings, and procedural milestones continue to shape what plaintiffs can expect in the months ahead. Whether you are a former patient or lost a loved one due to Oxbryta complications, here is what you need to know about where the litigation stands in 2026 and what’s likely coming next.
Why Oxbryta Was Pulled from the Market
Oxbryta (voxelotor) was prescribed to treat the painful symptoms of sickle cell disease, but post-marketing data revealed troubling safety risks. Patients taking the drug were experiencing vaso-occlusive crises (VOCs), strokes, organ damage, and fatal events at rates that outweighed any benefit. Pfizer issued a voluntary global withdrawal on September 25, 2024, and the FDA quickly followed with a public warning urging patients to stop taking the medication and consult their doctors.
Where Oxbryta Litigation Stands in 2026
The cases against Pfizer and Global Blood Therapeutics have moved into a settlement-driven phase, with federal coordination keeping the process organized under a single judge. Plaintiffs are still being added to the docket, and several individual cases have already been resolved.
Status Report Due May 22, 2026
The judge overseeing the federally coordinated Oxbryta cases has directed the parties to submit a status report on May 22, 2026. Court filings suggest the parties may soon ask the judge to review preliminary settlement terms, which could mark a major turning point in how the remaining claims are handled.
Individual Settlements Already Reached
Several plaintiffs have reached confidential settlement agreements with Pfizer and Global Blood Therapeutics ahead of the broader resolution. These include the case of Maurice Frazier, resolved in December 2025, and the case of Tirrell and Latoya Allen, resolved in October 2025. Both involved serious complications, including blood clots and stroke, after Oxbryta was prescribed for sickle cell anemia.
First Bellwether Trial Approaching in 2027
A federal court in California has scheduled what is expected to be the first Oxbryta case to reach a jury, with proceedings set to begin in September 2027. The outcome will likely influence how Pfizer approaches the remaining claims and could establish important benchmarks for damages in future cases.
New Lawsuits Continue to Be Filed
Even as settlement talks progress, additional plaintiffs are coming forward. A December 2025 California case filed by Laura Christine Matteliano-Madu over her husband’s death, and the active San Francisco case under No. CGC-24-621022, show that families are still discovering the link between Oxbryta and their loved ones’ injuries. Court filings from late 2025 confirmed at least 18 Oxbryta lawsuits pending in federal and state courts, with that number expected to climb.
Eligibility to File Remains Open
If you took Oxbryta and suffered a VOC, stroke, organ damage, or other serious complication, you may still qualify to file a claim. The statute of limitations has not closed, and surviving family members of patients who died after taking Oxbryta also retain legal options.
Speak With an Oxbryta Lawsuit Attorney About Your Options
As the Oxbryta litigation continues to evolve, having an attorney who stays ahead of every development can make a meaningful difference in the outcome of your case. Shapiro Legal Group, PLLC is actively tracking the litigation as it unfolds and is prepared to act decisively on behalf of clients harmed by this drug. Whether you are ready to file or still gathering information, contact us today to speak with an attorney who can help you navigate the road ahead.